Company Overview - ProKidney aims to transform the treatment landscape for patients with advanced chronic kidney disease, particularly those at high risk of kidney failure and potential dialysis [2][4] - The company's lead product, rilparencel, is positioned as a meaningful intervention to alter the progression of kidney disease towards failure [3] Market Context - There are over 3 million Americans currently suffering from advanced chronic kidney disease, with many facing a high risk of developing kidney failure in the coming years [4] - The majority of these patients will require dialysis, while a fortunate few may receive kidney transplants, highlighting the urgent need for effective treatment options [4]

ProKidney Conference Call Summary Company Overview - **Company**: ProKidney - **Industry**: Healthcare, specifically focused on chronic kidney disease (CKD) treatment - **Product**: Rilparencel, an autologous cell therapy aimed at treating advanced chronic kidney disease Key Points and Arguments Market Opportunity - Over 3 million Americans suffer from advanced chronic kidney disease, with many at high risk of kidney failure and requiring dialysis [2][4] - Rilparencel aims to provide a transformative treatment option for these patients, allowing them more time and flexibility in their lives [3] Product Development - Rilparencel has shown kidney function stabilization in multiple phase two trials, with over 150 patients treated [3] - The therapy has a favorable safety profile, requiring no preconditioning or immunosuppression [3][6] - A pivotal phase three study (PROACT 1) is ongoing, with a readout expected in Q2 2027 [5][19] Regulatory Progress - ProKidney has aligned with the FDA on an accelerated approval pathway using eGFR slope as a surrogate endpoint [4][17] - The company is actively engaging with the FDA under the RMAT designation [5] Manufacturing and Capacity - ProKidney is expanding its in-house manufacturing facilities in Winston-Salem, North Carolina, to support clinical and commercial needs [5][9] - The manufacturing process involves harvesting kidney cells from patients, expanding them, and then cryopreserving the product for injection [7][8] Clinical Study Insights - The phase three study design is robust, randomized, and sham-controlled, focusing on patients with type 2 diabetes and advanced CKD [17] - Enrollment is progressing well, with expectations to complete enrollment for the accelerated approval cohort by mid-2026 [29] Financial Position - As of September, ProKidney had $270 million in cash, sufficient to fund operations into mid-2027 [28] Efficacy and Safety Data - In a phase 2 study, the annual decline in eGFR slope improved by 78% after treatment with rilparencel [25][26] - No serious adverse events related to rilparencel were reported, indicating a consistent safety profile [26][27] Future Plans - ProKidney plans to continue R&D efforts to elucidate the mechanism of action for rilparencel, with data expected throughout 2026 [20][34] - Preparations for a Biologics License Application (BLA) submission and commercial launch are underway [39] Additional Important Content - The company recognizes the need for better representation of underrepresented patient groups in clinical trials and is actively working to address this in the phase three program [24][25] - The mechanism of action for rilparencel is believed to involve anti-inflammatory effects and the utilization of innate restorative mechanisms in the kidney [33] This summary encapsulates the critical insights and developments discussed during the ProKidney conference call, highlighting the company's strategic direction and the potential impact of its lead product on the treatment of advanced chronic kidney disease.

NASDAQ PROK Transforming the Future of Chronic Kidney Disease Treatment Preserving Kidney Function in Patients at High Risk of Kidney Failure 44th Annual J.P. Morgan Healthcare Conference Bruce Culleton, MD Chief Executive Officer January 14, 2026 Copyright © 2026 ProKidney Corp. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual ...

Group 1 - ProKidney Corp. (NASDAQ:PROK) is currently rated as a "buy" by over half of analysts, with a median price target of $6.50, indicating a potential upside of 152.92% from the current price [1] - Analyst Joseph Pantginis from H.C. Wainwright has set a price target of $12, suggesting a 367% upside from the current price [1] - The company is focused on a new approach to treating chronic kidney disease with its lead asset, rilparencel, which has the potential to redefine treatment methods [2] Group 2 - Rilparencel is an investigational autologous cell therapy that has shown promising results in Phase 1 and 2 trials, including improvements in estimated glomerular filtration rate (eGFR) and a positive safety profile [3] - The ongoing Phase 3 PROACT 1 trial has received FDA approval to use eGFR slope as a surrogate endpoint, which may facilitate an accelerated regulatory approval process for a Biologics License Application (BLA) [4] - ProKidney Corp. is a clinical-stage biotechnology company based in North Carolina, established in 2015, dedicated to transforming the treatment landscape for chronic kidney disease [5]

Summary of ProKidney Conference Call Company Overview - ProKidney is focused on addressing chronic kidney disease (CKD) in patients, particularly those at risk of requiring dialysis. The company is based in North Carolina and Boston, employing approximately 250 individuals aligned with its mission to keep patients off dialysis [2][3]. Product and Clinical Trials - ProKidney's primary product, rilparencel, is an autologous cell therapy currently in a Phase 3 clinical trial aimed at preserving kidney function in patients with advanced CKD [2][4]. - The company has made significant progress in its clinical studies, overcoming initial manufacturing challenges and achieving Good Manufacturing Practice (GMP) compliance [4][5]. - An accelerated approval pathway has been established with the FDA, allowing for a readout based on eGFR slope, with top-line data expected in Q2 2027 [5][14]. Clinical Study Details - The Phase 3 study is a double-blind, sham-controlled trial conducted at over 60 sites in the U.S., Taiwan, and Mexico, with a primary endpoint of a composite time-to-event measure [13][14]. - The study aims to demonstrate a 1.5 mL per minute per year difference in eGFR progression between treated and sham groups, with a 90% power to detect this difference [14][15]. - Enrollment is progressing well, with over 50% of participants already enrolled [5][17]. Efficacy and Safety Data - In a Phase 2 study (007), rilparencel demonstrated a 78% improvement in kidney function decline in one treatment group, while another group showed a 50% benefit, suggesting a dose-response relationship [5][9]. - Safety measures include strict eligibility criteria to minimize risks associated with kidney biopsies, and the company reports no serious events related to rilparencel [25][26]. Market Opportunity - The addressable market includes 1 to 1.5 million stage 3B and 4 CKD patients with diabetes in the U.S. A 1% market penetration could result in 10,000 to 15,000 patients treated annually [31]. - Rilparencel could potentially save the healthcare system up to $150,000 annually per patient by delaying the need for dialysis [31][32]. - The Medicare budget allocates 7% to manage end-stage kidney disease, indicating a significant financial burden that rilparencel aims to alleviate [36][38]. Financial Position and Future Catalysts - As of September 30, ProKidney has $272 million in cash, sufficient to fund operations through mid-2027 [40]. - Key upcoming catalysts include the Phase 3 data readout in Q2 2027 and additional data on the mechanism of action in the following year [40][41]. Conclusion - ProKidney is positioned in a promising market with a unique product aimed at a significant health issue. The company is on track with its clinical trials and has a solid financial foundation to support its upcoming milestones [41].

Core Viewpoint - ProKidney Corp. reported promising results from its Phase 2 REGEN-007 study, indicating that rilparencel may effectively stabilize kidney function in patients with advanced chronic kidney disease (CKD) and diabetes, supporting the ongoing Phase 3 PROACT 1 study [2][3][4]. Financial Highlights - As of September 30, 2025, ProKidney had cash, cash equivalents, and marketable securities totaling $271.7 million, down from $358.3 million at the end of 2024, which is expected to fund operations into mid-2027 [5][6]. - Research and development expenses for Q3 2025 were $26.8 million, a decrease from $31.3 million in Q3 2024, primarily due to reduced clinical operation costs [8]. - General and administrative expenses decreased to $11.9 million in Q3 2025 from $17.7 million in Q3 2024, mainly due to lower non-cash impairment charges [9]. - The net loss before noncontrolling interest was $35.8 million for Q3 2025, compared to $41.1 million for the same period in 2024 [10]. Clinical Updates - The Phase 2 REGEN-007 study showed a 4.6 mL/min/1.73m improvement in the annual decline in eGFR slope for Group 1, representing a 78% improvement, which was statistically significant (p<0.001) [7]. - Among Group 1 patients, 63% met the key PROACT 1 inclusion criteria, with a 5.5 mL/min/1.73m improvement in eGFR slope observed in this subgroup, indicating an 85% improvement (p=0.005) [7]. - The FDA has confirmed that the eGFR slope can serve as a surrogate endpoint for the accelerated approval pathway for rilparencel, with topline data readout expected in Q2 2027 [4][6]. Company Overview - ProKidney is focused on developing rilparencel, a first-in-class autologous cell therapy for patients with Stage 3b/4 CKD and diabetes, addressing a significant unmet need in the treatment of CKD [11][15].

Core Insights - ProKidney Corp. presented full results from the Phase 2 REGEN-007 trial, demonstrating the potential of rilparencel to preserve kidney function in patients with advanced chronic kidney disease (CKD) and diabetes [1][2][3] Phase 2 REGEN-007 Overview - The REGEN-007 trial was a multi-center, open-label, randomized study involving two treatment groups, focusing on different dosing regimens of rilparencel [4] - Group 1 followed the dosing schedule of the ongoing Phase 3 PROACT 1 study, while Group 2 tested an exploratory regimen based on disease progression triggers [4] - A total of 87 rilparencel injections were administered to 49 participants, with follow-ups extending up to 18 months post-injection [4] Efficacy and Safety Findings - Rilparencel treatment resulted in a statistically significant 4.6 mL/min/1.73m² (78%) improvement in the annual decline of estimated glomerular filtration rate (eGFR) slope in Group 1 [6][7] - Among Group 1 patients, 63% met key Phase 3 PROACT 1 inclusion criteria, with a 5.5 mL/min/1.73m² (85%) improvement observed in this subgroup [7] - Group 2 showed a 1.7 mL/min/1.73m² (50%) improvement in eGFR slope, although this was not statistically significant [8] - No serious adverse events related to rilparencel were reported, and the safety profile was consistent with previous studies [6][14] Phase 3 PROACT 1 Program Update - The Phase 3 PROACT 1 trial aims to further assess rilparencel's potential to preserve kidney function in patients with advanced CKD and type 2 diabetes [9] - The FDA confirmed that eGFR slope is an acceptable surrogate endpoint for the study, supporting both accelerated and confirmatory approval pathways for rilparencel [9] - More than half of the required 360 patients for the accelerated approval analysis had been enrolled as of August 2025, with topline results expected in Q2 2027 [9] About Chronic Kidney Disease - CKD is a progressive condition affecting approximately 37 million adults in the U.S., with diabetes being the leading cause [11] - ProKidney is targeting patients with Stage 3b/4 CKD and diabetes, a population estimated to include 1 to 2 million individuals in the U.S. [11] - There is a significant unmet need for therapies that can stabilize kidney function and delay or prevent the need for dialysis in advanced CKD patients [11] About ProKidney Corp. - ProKidney is a pioneer in cell therapy for CKD, with rilparencel being a first-in-class autologous cellular therapy currently in Phase 3 trials [12] - The company was founded in 2015 and has a decade of research backing its innovative treatment approach [12]

Core Insights - ProKidney Corp. has made significant advancements in 2025, particularly with positive topline data from the Phase 2 REGEN-007 study and alignment with the FDA on the accelerated approval pathway for rilparencel [2][3][7] Regulatory and Clinical Updates - The FDA confirmed that the slope of estimated glomerular filtration rate (eGFR) can serve as a surrogate endpoint for the accelerated approval of rilparencel, requiring an effect size of at least 1.5 mL/min/1.73m² per year improvement [3][4][7] - ProKidney anticipates topline data readout to support the accelerated approval application in Q2 2027, with over half of the required 350 patients already enrolled in the Phase 3 PROACT 1 study [4][7] - The Phase 2 REGEN-007 study showed a 78% improvement in annual decline of eGFR slope, from -5.8 to -1.3 mL/min/1.73m², with 63% of patients meeting key Phase 3 inclusion criteria [5][6][7] Financial Highlights - As of June 30, 2025, ProKidney reported cash, cash equivalents, and marketable securities totaling $294.7 million, down from $328.5 million as of March 31, 2025, expected to fund operations into mid-2027 [10][11][12] - Research and development expenses decreased to $25.9 million for Q2 2025 from $29.4 million in Q2 2024, primarily due to reduced clinical study costs [11] - General and administrative expenses increased slightly to $14.0 million in Q2 2025 from $13.7 million in Q2 2024, driven by higher cash compensation and operational expenses [12] Company Overview - ProKidney is focused on developing rilparencel, a first-in-class autologous cellular therapy for chronic kidney disease (CKD) patients, particularly those with diabetes and advanced CKD [18][14] - CKD affects an estimated 37 million adults in the U.S., with diabetes being the leading cause, highlighting the significant unmet clinical need for effective treatments [14]

Core Viewpoint - ProKidney's stock experienced a significant increase due to positive trial results for its lead candidate, rilparencel, aimed at treating late-stage chronic kidney disease (CKD) [2][4][5] Group 1: Stock Performance - ProKidney's stock rose from less than $1 per share at the end of June to $5.18 per share by July 10, marking a 775% gain in just 10 days [1] - As of July 18, ProKidney's market cap was $408 million, indicating a low valuation for a company potentially launching a treatment for over a million patients [15] Group 2: Clinical Trial Results - The phase 2 Regen-007 trial results showed that treatment with rilparencel stabilized kidney function, with a 78% slower decline in eGFR for patients receiving two injections compared to the placebo group [6][10] - A secondary group receiving a single injection showed a 50% lower annual rate of eGFR decline compared to the placebo, but the sample size of 25 patients was not statistically significant [11][10] - ProKidney is currently enrolling patients in a phase 3 trial, with results expected in 2026 [9][12] Group 3: Regulatory Insights - ProKidney's management reported positive feedback from the FDA regarding the approval path for rilparencel, with the agency accepting improved eGFR decline rates as a surrogate endpoint [13] - This could allow ProKidney to submit an application package to the FDA before the end of next year [13] Group 4: Financial Position - ProKidney ended March with $328.5 million in cash after a burn of $38 million in the first quarter, indicating sufficient resources for ongoing operations [16]

Core Viewpoint - ProKidney Corp. has received confirmation from the FDA regarding the accelerated approval pathway for its autologous cellular therapy, rilparencel, aimed at treating chronic kidney disease (CKD) in patients with type 2 diabetes, marking a significant regulatory milestone for the company [1][3][6] Group 1: FDA Confirmation and Clinical Trials - The FDA confirmed that the estimated glomerular filtration rate (eGFR) slope can serve as a surrogate endpoint for the accelerated approval of rilparencel, with an effect size of at least 1.5 mL/min/1.73m²/year required to demonstrate efficacy [2][6] - ProKidney anticipates topline data readout supporting the accelerated approval application in Q2 2027, with nearly half of the required patients already enrolled in the ongoing Phase 3 PROACT 1 study [2][6] - The ongoing Phase 3 PROACT 1 study may also serve as a confirmatory study for full approval based on the primary time-to-event composite endpoint specified in the protocol [2][6] Group 2: Chronic Kidney Disease Context - Chronic kidney disease (CKD) affects an estimated 37 million adults in the U.S., with diabetes being the leading cause, significantly increasing the risk of cardiovascular events and mortality [4] - ProKidney is focusing on patients with Stage 3b/4 CKD and diabetes, a population estimated to include 1 to 2 million individuals in the U.S., highlighting the substantial unmet need for effective therapies [4] Group 3: ProKidney's Product and Strategy - Rilparencel is a first-in-class, patented autologous cellular therapy developed to preserve kidney function in diabetic patients at high risk of kidney failure [7] - The Phase 3 REGEN-006 (PROACT 1) trial is a randomized, blinded, sham-controlled study with a planned enrollment of approximately 685 subjects, focusing on patients with advanced CKD and type 2 diabetes [5][6]